Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women

Maturitas

Volumn 58, Issue 2, 2007, Pages 138-149

  Diaby, Vakaramoko ^a   Perreault, Sylvie ^a   Lachaine, Jean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Hormone Replacement Therapy; Menopause; Pharmacoeconomic analysis; Policy makers; Tibolone

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ETHINYLESTRADIOL PLUS NORETHISTERONE; PREMPLUS; TIBOLONE; UNCLASSIFIED DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG INDICATION; ECONOMIC ASPECT; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; OUTCOME ASSESSMENT; POSTMENOPAUSE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SPOTTING; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; VAGINA BLEEDING; WOMEN'S HEALTH;

CANADA; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; MARKOV CHAINS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; NORPREGNENES; POSTMENOPAUSE; QUALITY-ADJUSTED LIFE YEARS;

EQUIDAE;

EID: 34948898587     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2007.07.004     Document Type: Article

References (35)

1. Conférence canadienne de consensus sur la ménopause et l'ostéoporose 2000/2001.Tiré à part du JOGC 2001; 23 (12):1-97.
2. Writing group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomised controlled trial. JAMA 2002; 288:321-33.
3. Barnabei M., Grady D., Stovall W., et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 100 (2002) 1209-1218
4. Greendale A., Reboussin A., Hogan P., et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 92 (1998) 982-988
5. Utian H., Shoupe D., Bachmann G., Pinkerton V., and Pickar H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 75 (2001) 1065-1079
6. Cauley A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density-The Women's Health Initiative randomized trial. JAMA 290 (2003) 1729-1738
7. Hammar M., Christau J., Rud T., and Garre K. A double-blind, randomised trial comparing the effects of Tibolone and Continuous Combined Hormone Replacement Therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 105 (1998) 904-911
8. Archer F., Pickar H., Bottiglioni F., and Menopause Study Group. Bleeding patterns in post-menopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 83 (1994) 686-692
9. Modelska K., and Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 87 1 (2002 Jan) 16-23
10. Coyle D., Cranney, and Tugwell P. Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms. Pharmacoeconomics 21 9 (2003) 661-669
11. Drummond F, O'Brien J, Stoddart L, Torrance W. Méthodes d'évaluation économique des programmes de santé, Deuxième Edition 1997.
12. Pilon D., Castilloux M., and Lelorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 97 (2001) 97-100
13. Simon J.A., Wysocki S., Brandman J., and Axelsen K. A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause 10 3 (2003) 37-44
14. Huber J., Palacios S., Berglund L., et al. Effects of Tibolone and Continuous Combined Hormone Replacement Therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 109 (2002) 886-893
15. Botteman F., Shah P., Lian J., Pashos L., and Simon A. A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms. Menopause 11 3 (2004) 343-355
16. Plumb J.M., and Guest J.F. Economic impact of Tibolone compared with Continuous Combined Hormone Replacement Therapy: in the management of postmenopausal women with climacteric symptoms in the UK. Pharmacoeconomics 18 5 (2000) 477-486
17. Manuel de facturation des omnipraticiens. Available at: http://www.ramq.gouv.ca/fr/professionnels/medomni/manuel/manu_tdm.shtml.
18. Manuel de facturation des spécialistes. Available at: http://www.ramq.gouv.ca/fr/professionnels/medspe/manuel/man150.shtml.
19. Régie de l'Assurance Maladie du Québec. Available at: http://www.ramq.gouv.qc.ca.
20. Drug tariff online. Available at: http://www.drugtariff.com.
21. Laupacis A., Feeny D., Detsky A., and Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization?. Can Med Assoc J 146 4 (1992) 473-481
22. Daly E., Roche M., Barlow D., et al. HRT: an analysis of benefits, risks and costs. Br Med Bull 48 2 (1992) 368-400
23. Tosteson A., and Weinstein C. Cost-effectiveness of Hormone Replacement Therapy after the menopause. Baillières Clin Obstet Gynaecol 5 4 (1991) 943-959
24. Cheung P., and Wren G. A cost-effectiveness analysis of Hormone Replacement Therapy in the menopause. Med J Aust 156 (1992) 312-316
25. Le Pen C., Maurel F., Breart G., et al. The long term effectiveness of preventive strategies of osteoporosis in postmenopausal women: a modelling approach (1997), SNIP, Modélisation, Paris
26. Visentin P., Ciravegna R., and Fabris F. Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. Maturitas 26 (1997) 185-192
27. Meunier J., Delmas D., Eastell R., et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. Clin Ther 21 6 (1999) 1025-1044
28. Brown A, Coyle DA, Chen S, Cumming DC, Mensinkai S. Transdermal Hormone Replacement Therapy patches for women with postmenopausal symptoms: economic analysis of short-term use. CCOHTA. Technology Report 2006. Issue 61.
29. Nathorst-Böös J., and Hammar M. Effect on sexual life-a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 26 (1997) 15-20
30. Castelo-Branco C., Vicente J., Figueras F., et al. Comparative effect of estrogens plus androgens and Tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34 (2000) 161-168
31. Egarter C., Huber J., Leikermoser R., et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 23 (1996) 55-62
32. Palomba S., Di Carlo C., Morelli M., et al. Effect of Tibolone on breast symptoms resulting from postmenopausal Hormone Replacement Therapy. Maturitas 45 (2003) 267-273
33. Bedenek-Jaszmann J. Long-term placebo-controlled efficacy and safety study of ORG OD 14 in climacteric women. Maturitas Suppl 1 (1987) 25-33
34. Walker I., Davidson A., Yates R., and McEwan P. The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in postmenopausal women. Thromb Haemost 53 (1985) 303-305
35. Canadian Consensus Conference on Menopause. JOGC 2006; 28:1-93.